Peter MacCallum Cancer Centre
Melbourne, Australia
Publications on this disease30
Research view
Switch to patient viewTriple-negative breast cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target or a country to narrow the list.
- All targets
- PD-L1 26
- HER2 24
- PD-1 36
- BRCA1 5
- STAT3 1
- STING 0
- EGFR 4
- PI3K 1
- BRCA2 2
- TP53 1
- AKT 0
- PARP 1
- mTOR 0
- TROP2 6
- AR 1
- PTEN 0
- CDK4/6 3
- VEGF 4
- HIF-1 0
- MYC 0
- GPX4 0
- YAP 0
- CTNNB1 0
- JAK 1
- HDAC 0
- MAPK 0
- BCL-2 0
- CXCR4 1
- ERK 0
- NRF2 0
- PPAR 0
- B7-H3 4
- EZH2 0
- FAK 0
- PRMT5 0
- CD47 0
- HSP90 0
- PSMA 4
- IL-6 0
- PIK3CA 2
- CTLA-4 1
- HER3 2
- TNF 0
- COX-2 0
- IGF1R 0
- MEK 0
- FGFR 0
- MDM2 2
- MET 0
- MUC1 3
- NLRP3 0
- PALB2 0
- AMPK 0
- CD40 0
- CSF1R 1
- JNK 0
- METTL3 0
- MMP-9 0
- PKM2 0
- SIRT1 0
1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NCI · R15
NIH NCI · R44
Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer
NIH NCI · K99
Unlocking Natural Killer cell potential to combat breast cancer metastasis
NIH NCI · R43
NIH NCI · R43
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE
European Commission (Horizon Europe) · HORIZON-EIC
Next generation therapeutic vaccine for targeted cancer treatment (VacciNEXT)
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
Co-culture System with Microfluidics and Onboard Sensors for Breast Cancer study (CoSMOS-BC)
The disease is named only in the funder's project summary, not in the title.
10 of 463 running projects, newest first. Listed amounts together: US$224.4m + €18.5m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
“The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 46
- Organoids 9
- Mendelian Randomization Analysis 2
- CRISPR-Cas Systems 10
- Gene Expression Profiling 110
- Sequence Analysis, RNA 8
- Whole Genome Sequencing 4
- Exome Sequencing 5
- Proteomics 32
- Metabolomics 14
- Mass Spectrometry 3
- Flow Cytometry 11
- Immunohistochemistry 49
- Liquid Biopsy 4
- Circulating Tumor DNA 16
- Xenograft Model Antitumor Assays 254
- Positron-Emission Tomography 13
- Magnetic Resonance Imaging 34
- Machine Learning 28
- Deep Learning 15
- Cohort Studies 21
- Genome-Wide Association Study 3
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.